Gnant et al. presented the final results of the Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) trial after a median follow-up of 94.4 months [1]. Although there was no disease free survival (DFS) difference between patients who received ovarian function suppression (OFS) plus either tamoxifen or anastrozole, patients treated with anastrozole + OFS had a significantly worse overall survival (OS) compared with patients treated with tamoxifen + OFS (hazard ratio = 1.63; 95% confidence interval 1.05-1.45; P = 0.030). These results contradict the results of the combined analysis of SOFT/TEXT trials which showed that 5 years of an aromatase inhibitor (AI) + OFS was associated with a superior DFS when compared with 5 years of tamoxifen + OFS and similar OS. Moreover, these results also contradict the results of numerous trials in the postmenopausal setting that have consistently shown a clear superiority of AI over tamoxifen in DFS and in some trials even an OS benefit [2].
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This raises a relevant question regarding the design of the Austrian study and the importance of the duration of adjuvant endocrine therapy, which was only 3 years in the ABCSG-12 trial. Although the authors referred to discrepancies in postrelapse therapy as a possible confounding factor to the poorer OS in the anastrozole arm, they did not address whether some patients were offered further adjuvant therapy 'off study' beyond the initial 3 years. Unless the study protocol controlled treatment beyond 3 years and in light of its open-label design, it is plausible that many patients in the control arm (tamoxifen + OFS) would have been offered by their treating physician additional tamoxifen to complete the classic 5-year therapy [3] . In contrast, a continuation of adjuvant therapy beyond 3 years would less likely occur in the investigational arm (anastrozole + OFS) where extension of endocrine therapy is not supported by evidence in the premenopausal setting.
This would make it difficult to interpret the hazard rate beyond the initial 3 years of treatment. Indeed, in the first report of this trial (4-year follow-up), the OS difference between the two arms was not statistically significant [4] . In a subsequent report (5-year follow-up), the authors began to observe a significant survival difference in favor of the tamoxifen arm as well as a similar difference in the subset of patients who had relapsed [5] . However, as the survival estimates of this subset analysis were calculated from the time of randomization, this could also potentially be confounded by heterogeneity in the duration of the adjuvant endocrine therapy between study arms.
These challenges are not unique to the current study, but would be less of an issue in interpreting the initial results of the SOFT/TEXT trials (median follow-up 5.6 years) where treatment is given for the standard 5 years. This may however confound longer follow-up results as extended tamoxifen beyond 5 years becomes more widely adopted. We agree that use of this schedule may represent a step before dose reduction in patients who have experienced dose-limiting toxicity, especially those who experience the onset of toxicity during the third and fourth week in the 4 weeks on, 2 off schedule. On the other hand, caution should be exercised when patients experience toxicity in the first 2 weeks of therapy with a standard schedule, in which a dose reduction to 37.5 mg/day with the 4 weeks on, 2 off schedule remains the standard of care.
Regarding data on patient outcome, these should be handled with care, bearing in mind that patients treated with the 2 weeks on, 1 off schedule in retrospective series received the new schedule just after the occurrence of dose-limiting toxicities such as 'hand-foot syndrome'. It has been reported in a previous article in this journal that several sunitinib-related toxicities (e.g. arterial hypertension, hand-foot syndrome, hypothyroidism) may have a predictive and prognostic role in mRCC patients [2] .
Moreover, a retrospective study carried out on an Italian cohort of more than 200 patients treated with alternative schedules of sunitinib reported an improved safety profile and a median treatment duration (TD) and a median progression free survival (PFS) of 28.2 and 38.6 months, respectively, in patients who started with a 4 weeks on, 2 off schedule and shifted to 2 weeks on, 1 off after a median period of 4.3 months. On the other hand, in patients who immediately started with a 2 weeks on, 1 off schedule, a median TD and PFS of 7.8 and 9.6 months, respectively, was reported [3] .
Considering its retrospective nature, this study, similarly to others reviewed by Kalra et al. cannot prove that a 2 weeks on, 1 off schedule is more active compared with the standard one, but confirms that patients such as those who experience treatment-related toxicities might have a better outcome. In addition, it should be taken into account that the overall survival rate may be conditioned by the duration of the first-line therapy [4] ; therefore, patients who change schedule during the treatment may have a longer survival compared with those that start with the alternative one.
Finally, alternative 2 weeks on, 1 off schedule should not be used in all patients who experience 'dose-limiting toxicity' but only for patients who had 'schedule-limiting toxicities' during the third and fourth week of treatment in order to maintain dose intensity. At present, considering the lack of data, clinicians should avoid the use of the 2 weeks on, 1 off schedule at the beginning of therapy outside of a clinical trial. 
